Centene (CNC) Q4 2025 earnings review
Margin Collapse Overshadows Revenue Growth
Centene ended 2025 with a chaotic fourth quarter, reporting an Adjusted EPS loss of $(1.19) as medical costs spiraled out of control across Commercial and Medicare segments. While Premium Revenue grew 23% YoY, the consolidated Health Benefits Ratio (HBR) deteriorated significantly to 94.3%. Management has shifted strategy from growth to contraction, guiding 2026 revenue down to $170-$174B (vs $174.6B in 2025) to purge unprofitable membership. The 'turnaround' story rests entirely on 2026 guidance of >$3.00 EPS, but credibility is strained after a year of massive impairments and missed operational targets.
🐂 Bull Case
Management is explicitly shrinking the business. 2026 guidance forecasts a revenue decline (approx -2% to -4%) but a significant EPS jump to >$3.00, suggesting they are successfully shedding unprofitable Marketplace and Medicare membership.
Amidst the chaos, the core Medicaid business showed sequential improvement. Medicaid HBR improved 40 bps QoQ to 93.0% in Q4, indicating that redetermination headwinds and rate discussions are finally stabilizing.
🐻 Bear Case
Commercial HBR spiked to 95.4% (up 1,360 bps YoY) and Medicare HBR hit 96.1% (up 940 bps YoY). These are catastrophic levels for an insurer, indicating massive pricing errors and utilization headwinds that may not be easily fixed by one repricing cycle.
After a year containing a $6.7B goodwill impairment, a guidance slash in Q2, and now a Q4 operating loss, investor trust is low. The 'net out of period items' cited for Q4 weakness raises concerns about visibility into claims data.
⚖️ Verdict: 🔴
Bearish. The company is shrinking to survive. While the 2026 guidance suggests a recovery, the operational reality of Q4 (negative earnings, 94%+ HBR) is dire. Execution risk is extremely high.
Key Themes
Commercial & Medicare Margin Blowout
The margin deterioration in Q4 was severe. Commercial HBR jumped to 95.4% (vs 81.8% in 24Q4) and Medicare HBR to 96.1% (vs 86.7% in 24Q4). Management cited 'net out of period items' for Commercial and IRA impacts for Medicare, but the magnitude suggests fundamental underwriting failures in the 2025 book.
PDP Revenue Surge (Empty Calories?)
Medicare revenue grew 75% YoY in Q4 to $9.6B, driven largely by Part D (PDP) membership growth. However, given the 96.1% HBR in the segment, this growth appears to be profitless or loss-making. The company is actively exiting unprofitable PDP business for 2026.
SG&A Discipline
The one operational bright spot remains cost control. The Adjusted SG&A ratio improved significantly to 7.5% in Q4 (from 8.9% YoY) and 7.4% for the full year. As the company shrinks revenue in 2026, maintaining this efficiency will be critical to hitting the $3.00+ EPS target.
Asset Impairments Continue
Following the massive $6.7B goodwill impairment in Q3, Centene recorded another $513M pre-tax impairment in Q4 related to the divestiture of Magellan Health. This continued cleanup of the balance sheet weighs on GAAP results and highlights past capital allocation errors.
Strategic Contraction
Management has officially pivoted from growth to shrinkage. 2026 guidance calls for Premium Revenue of $170-174B, down from $174.6B in 2025. This confirms the exit from unprofitable Marketplace states and Medicare plans discussed in previous quarters.
Other KPIs
Decelerating. Ended significantly below the original 2025 guidance of >$7.25 given at the start of the year, and just barely cleared the lowered 'at least $2.00' bar set in Q3. The operational deterioration in H2 was profound.
Stable/Declining. Down 2 days sequentially from 48 days in Q3. Management attributes this to state-directed payments and elimination of premium deficiency reserves, but a falling DCP in an environment of rising medical costs warrants close monitoring.
Weak. While positive, $437M is thin for a company generating $49B in quarterly revenue. Full year OCF was $5.1B, showing that Q4 was impacted by timing of payments/rebates and the operating loss.
Guidance
Accelerating. Implies a ~44% increase from 2025's $2.08. This relies heavily on margin expansion (HBR dropping from 91.9% FY25 to ~91.3% FY26 mid-point) rather than revenue growth.
Reversing. Down from $174.6 billion in 2025. This intentional contraction (-0.3% to -2.6%) is a major strategic shift to exit unprofitable business lines.
Improving. The midpoint (91.3%) represents a 60 bps improvement over 2025's 91.9%. Given Q4 2025 was 94.3%, this implies a massive and immediate turnaround in medical cost trends.
Key Questions
Commercial HBR Visibility
Commercial HBR spiked to 95.4% in Q4 due to 'out of period items.' How can investors trust the 2026 pricing inputs if 2025 claims data was this volatile and visible only in hindsight?
Magellan Divestiture
With another $513M impairment recorded for Magellan, what are the remaining financial risks or cash drags associated with the full exit of this legacy acquisition?
Medicare Turnaround Structural vs. Temporary
Medicare HBR deteriorated to 96.1%. Is the improvement baked into 2026 guidance purely a function of shedding members (denominator effect), or have you seen actual unit cost stabilization in the retained book?